[Non-English content]
Welcome to the divulgation results from third semester from Ouro Fino Saúde Animal Health. I am Juliana Matthes, I am part of the communication team, and it is a pleasure being here with you guys so we can conduct this meeting. This transmission is being recorded and it is going to be available on our site, on our relationship site with investors, ri.ourofino.com, and also on our YouTube channel, youtube.com/ourofinosaudeanimal. At the end of the meeting, we are going to have our Q&A round and please, if you want to make a question in advance, all you got to do is just use the Q&A sector.
We got a very cool notification that I am actually going to start with. This presentation brings declaration over events or future events. They are subject to risks and uncertainties. Such declarations as a base, disposition of our administration and information for which the company actually has access to.
Declarations over further events, including information over our intentions, beliefs, or expectations, or current expectations, just as the ones from the administrative board and company director. Notifications relating the declarations, information over the future always include information over operational results that have been expected, such as declaration has been preceded, followed, or include the words "believe," "will," "is going to," "continue," "predicts," "intends," "plans," "estimates," or similar expressions. The information and declarations over future are not performance guarantee. They involve risks, uncertainties, and suppositions because they are related to future events, depending, of course, over circumstances that may not or may occur. Future results and value creation for shareholders are actually going to have a significant way from those expressed or suggested for declarations regardless. Many of the factors that will determine if these results and values are beyond our capacity or our provision control.
So we can conduct the presentations, we count with the presence of our CEO, Kleber Gomes, of our Development and New Business Director, Angelo Melo, and our Supervisor of the Investor Relations, Bruno Menegazzo. So we can start our presentation route. I am going to have the word of the CEO. Good morning, Kleber.
Thank you a lot. Thank you, everyone. Today Marcelo is going to be absent. We are going to miss him. He is at home today, but he is actually watching us. Going to make the presentation over with Bruno. Everybody already knows him. I am happy for the trimester. It has been very productive over quality with positive margins out of what we had aligned before. We had a very productive second trimester. Very good one and a positive second trimester, and we have actually been very steady.
Our purpose is actually deliver a very good year, just as many years of 2020 and 2021. In this semester, beyond the very good result that we had, we are following the very good actions with very expansion of knowledge base, we are going to explore it a lot during the presentation with you. First of all, I am going to make a few highlights. First of all, we are a company that actually focus in animal health and agribusiness is actually our main line. We felt the necessity to reinforce all the positive actions inside the agro field, inside the market. We have been building a very positive market campaign with regards to positivity. We had actually been working a lot on our internal expertise regarding marketing.
We have been to Expoagro, a fair where Expoagro, and also the hashtag for our main campaign, which means to bring out for the general public in general, not only the agribusiness, but for the people in general, the importance of agro in our daily business and everything that we do, we see agro. We are going to make available a lot of pieces, but a campaign that there is no release date to actually make an end, so everyone can help feed on this positive politics that we are actually inside, that we have actually inside Brazil. We have a very big participation inside the country and in the market, and this kind of initiatives are going to help us further the cause.
We have got a lot of people who have got knowledge in the line of what has been already going on regarding the people that have been involved inside the market and the weather that we have received and the GPTW ranking that we have received as well. We took first place in agro category. The third place in our countryside of São Paulo for the national category. We have been inside the scope of 9,000 collaborators inside the companies for the 150 best companies for the market. When it comes to regarding the knowledge that we have assembled. It is something around more than 100 companies that have been actually taking part in this fair. To be top three inside these companies is something really, actually to feel proud of. Even so, when you are actually being inside of the top 50 position inside a presentation.
I am pretty happy with all the knowledge that we have provided, all the people and experiences we have met, the practices that we have been working on inside our databases. We have the renouncement from VOCÊ. We have been renowned by them in a very cool way, for a very good place, actually, in the pharmaceutical field to work on. We took 13th position inside of all companies in this ranking, it is a very good, excellent number. Between eighth position between a category for big enterprises and the best one in pharmaceutical sector.
Inside these animal pharmaceuticals and human pharmaceuticals market, we have been actually taking eighth place, so we have been actually very happy with the first place. We have been working on the open innovation sector as well, seeking the refreshment of the world in a basis that we can allow us to produce, grow bigger in the market.
We are one of the biggest companies that makes connections with startups in the whole market. We took second place in that ranking when it comes to agribusiness. We have Embrapa as well, who is the barn for agribusiness in Brazil. We are ahead of many bigger enterprises inside the business. We have already made over 45 contracts with many startups, considering the acquisition, the recent acquisition from the technology platform from stem cells in the business. We are very happy with the condition of our recent product releases. We had, throughout the year, many very good products. We are going to recalculate all these things along the meeting, but I wanted to highlight the most recent releases that are Beniv. Beniv is pet analgesic. It is pretty innovative, the first molecule from Protaphane that has already been marketed in a veterinary market.
We counted with the help, further our cost to get the approval inside the market. This is one of the many solutions that we have come in the market to make it useful. Now we have a natural additive antibiotics that is actually fully 100% natural. We have been doing a very good process with our Asian enterprises inside the business and a strategic business that we have, and these additives will make a trend for rational use, for probiotic use in the production of birds and other kinds of. It is a very complete line. It has already been available, in a long time it is going to gain some relevance inside the market, our gross profit. In the end, but not less important, everybody knows we have been communicating with the market.
The illusion, the push abolition, it has been a very exciting process we had and amazing features that we had Mitsui in Japan, along with opportunity, we had a very nice opportunity with us. We are very happy to receive the consortium from Mitsui. Century over age from Mitsui, one of the biggest in Japan, one of the biggest in Asia as well. It is a company with more than $120 billion in investment, with more than 500 units working in relationship. Fantastic thing to actually come about. We have the honor to actually be renowned at a market with, as a vehicle, as a new division in animal healthcare, and we are being pioneers in this area, and it is a very good thing here in Latin America, where we tend to expand our business to Asia, Europe.
We have a very good result, a very good response on that over the market worldwide, and we have been expecting very good results in mid-long term. Our semester has been very turbulent, but in a way that we like it, in a very smooth way and a very rushy with excellent productivity, knowledge being spread out. As always, we are always planting seeds for the future. We work in a very aligned with all the sectors inside those projected and adaptations that we need along the way. Thank you very much. I am going to give the word back to Ju so she can continue with the presentation. I will be back with you for questions in the Q&A round.
Thank you a lot, Kleber. Remembering at the end of the presentation, we are going to open for the Q&A round. You can make a question since now, right over here in the Zoom section on the Q&A sector. We have been talking with Angelo Melo, the presence of our director for positions for new business and to present the new solutions of our portfolio. Good morning, Angelo. You have a presentation.
Good morning, Juliana. Good morning, everyone. Pleasure being here again. We are here again to talk about releases of new, as we have committed before, on beginning of the year. Portfolio management and the release of new products is extremely important for our strategic plan because they are the source of growth and inside of gross profit, it is the most important thing. This sort of day, we have actually been bearing 14 new products that has already been released, the last product being the natural additive by the end of this month. We have gone with Tulaxx, the cross-patented product for pneumonia product control. We were the first in the market actually to release this product ever. The release being made after the second trimester, and results are actually being fantastic, being well-received in the market. We have actually been renowned in the market for this.
It actually is a beacon for a good initiative when it comes to animal producing owners in questions of produce safety and quality and technical services. It is a very important mark that we need to point out for. We also released, along the third trimester, the supplements for animals. We have actually been releasing six products of them, and these supplements are inside a concept of anthropomorphism. It is a concept what moms and fathers of pets do the same with their human kids, they would like to have the same kind of treatment with their pets. Sort of supplement markets, it is a very pungent market when it comes to human healthcare, and we are actually trying to replicate the same scenario to animal market.
It is a very powerful version for growth inside our business, inside our strategic plan, because it is a very expanding, very fast market with few players, few segmented players in it. We are pretty trusting that these six products are actually going to come with a lot, with new things coming over, and we are seeing it with good eyes. Beginning of the third trimester as well, we have been with the released product with this Beniv. It is a product based on buprenorphine. A product indicated for extremely over pre, during, and post-surgery, completely handled by the veterinarian. It has got indication for cats and dogs. The same kind of product actually covers both the species, which financially for us is more important because it helps the opportunity of actually gross profit increase. The thing is the veterinarian can actually work with the same product for both species.
It makes the lives of our clients a lot more easier. The most important thing in Beniv still is innovation. We are the first company ever to bring buprenorphine to the market, so we can actually show our capacity to innovate, to detect problems, and actually direct these products to the animal world. Another very important thing that this specific product means innovation. Inside the line of market for fast track, we have the Ministry of Health actually looking over this. There are a few nuances that needs approval inside this product in a market, in a worldwide market. This regulation system actually make a fine point in here. They made a product fit inside the rules, inside a fast track norm, and the verification product date has actually been inside the ministry. The whole process actually took almost a year, 11 months and a few days.
We almost took two years to make everything viable, so we actually shown lots of expertise in terms of time consuming, time saving, releasing the specific product. For the last bit, we are actually releasing now this month, the natural additives, non-antibiotic additives. The line for birds, pigs, it is a globalized market worldwide. Brazil is the biggest exporter when it comes to this kind of product, pig meat and chicken meat, so we are completely focused in that market. These products are actually being aligned according to the market current insight and their demands when it comes to antibiotics. These products have been developed inside a concept of client, inside a the core, inside a committee for specialists and all the other departments included. We actually wanted to make sure that their demands were met when it comes to the performance additive market.
It was a market that used to have the use of a lot of antibiotics in the market, but now it is reducing, so we are trying to make it fast in a way possible and more effective. We actually met their necessities that previously were not met with the clients. Starting from that, we actually designed these products along with them, and we are going to look for other global partners to actually to make our values connected to the world. We have identified partners around the world in Asia and Europe, and we are releasing six products. These products are probiotics, essential oils, combined products with oils, with organic acids which have no prescription, which have no bureaucracy regarding the release date of those products. They are actually compromised to make equilibrium inside the intestinal and gain weight inside the animal world.
These products have been developed with our global partners. We have worked with three Brazilian universities, USP, Universidade Federal de Lavras, and Universidade Estadual de Londrina as well. At these universities, we made eight clinical studies and at several stages when it comes to growth animal stages, and the positioning that we have, we created along with our clients. There was an excellent performance inside all these stages and what we have predicted inside our design, our project. We have been bringing the full package when it comes to technology and how to use this technology in the field and how to make productivity increase in a general way. Finishing here, before getting back to Juliana, really wanted to reinforce our commitment with innovation of product release that we talked about in our Ouro Fino hearing. We are actually releasing 14 new products. Thank you so much. Back to Juliana.
Thank you for your participation as well. For your presentation. That's right. Let's start our portfolio. We come to our results. Today, we've actually been counting with the presence of Bruno Menegazzo, making his presence here with us. Although he's pretty known to all of us, all of the team. Bruno is our financial manager and relationship with investors. Bruno, welcome. Thank you so much for your presence and good presentation from you.
Thank you, Ju. Thank you, everyone. Good morning. Let's talk about the financial highlights that we have. It's pretty important that we wanted to bring to you guys overview of how we're standing in financial terms since we made a strategic plan in 2019, and we have linked six work fronts and actually been winning and been delivering them to the director's board with very good numbers when it comes to releases, with the commitment, with products such as Kleber commented. But mainly here, I wanted to provoke the financial outcomes that we had throughout these years. We had a 13% growth since 2019, and this new cycle that has begun, we have accumulated growth actually along these years for 70%.
Our gross profit has actually reached more than 51%, showing the resilience of our business apart from all the challenges that we had throughout the market for the last calls that we had. And generation for the profit actually, the operational profit is more, has been along BRL 90 million for along these accumulated months. With that, we can bring data to boost to more than 1.3 x from EBITDA. And the last growth from 10% a year under selling stages, under selling growth when it comes to retaking the BNDES would make for a very elongated period instead of 79% when it comes to long-term. A few of the results that we have accumulated, this 70% of growth of the company along these months since 2019 represented a growth of 19.5%
The management of rentability and inside every trimester has actually made a dense 19% growth along the years and with a very third for the other ones. Going to our BUs, we have production animal sector with very expressive growth numbers as well since 2019. It's come up to 66%, with a gross profit recovery when it comes to that terms, apart from all the logistic challenges that we have. And this third trimester, we had the stale production period, and it's always good to bring that up on our talks because it's been a success as well. So it helped us on our overall numbers.
About the nine months that I had stipulated before in our third talk, we still have the Aftosa vaccines that are being sold on the second trimester, but now on the fourth trimester, for the subsequent trimester, we have sales that occurred in the last few days according to what we had foreseen in our business. For companion animals, we had a very important growth from trimester to trimester. Growth being expected inside since 2019 in the house of 30%. We have supplements as well inside our market for the diagnostic kits. Just like we pointed out last year, we received those kits, we made the sales. So we are walking towards an alignment here, although we are facing challenges inside of families that we have commented before.
Instead of actually going to the pet market, going for other supplements that do not have the same kind of development for the past year, just like 2020 or 2021. On the other side, we understand that our drive for the conductor is something very valid given the fact that our products have been very well received in the market, and recurrence actually from the supplement parts to superficial medicaments. Transforming into multiple core animals. Resources forces. We have always committed to the challenges that we had. It was not different this trimester when it comes to volatility. It is a very high volatility. On the other hand, it ended up impacting the gross profit for this week ahead, simple. For, we have been growing in a local market as well. Inside our expectations, especially when it comes to Colombia and Mexico. Mexico, we have been facing a greater challenger.
But for the release date, we have a macro-economical scenario and the unfolding economical issues inside Colombia needs a bit of attention. On the other hand, our growth from other countries, although the current scenario that we are facing right now has been very positive, just like we have committed before, for a matter of container occupation, we have been actually replacing a very good strategy inside the market. This DNA inside a company, SG& A, inside of what we have of the effort that we made through the administration in a minute, and actually lowering our numbers for the production even for the whole year, even if it is compared to the trimester. Even when it comes to the city from last year, we have still had a betterment from inflation even though we had a very negative scenario inside our political scenario.
Even though with all those challenges we managed to lower cost of productivity inside our company. When it comes to P&D, we have seen a slight raise. But when it comes to actually making fast for the acceleration of the products inside the market, Kleber and Angelo have been working on it a lot. We have been doing a very good margin for the products release. Juliana has been helping a lot. Have the pieces of the product for P&D. Together, all together, they actually make for the company's growth, that we have something a bit more tangible instead of highs of 8% when it comes to respite. It is a bit above the average of what we have in historical for 7.5. But inside our pressing plan for the new technologist program and advanced plans that we have been investing inside the company.
In the end, just finalizing here, EBIT been adjusted, been showing resilience numbers, including if we make a comparison for the past three years in a high of 79%. Now we have 120% for EBIT accumulated since 2019. That shows a lot, something that we had commented before when it comes to strategic project for commercial synergy. Many positive things that actually made a result in our company, which is the final result of the growth that we have, and we're pretty excited for the rest of the year for the results that we have achieved so far. It's important to actually mention when it comes to gross profit again. We've been doing a very good job, which is worth mentioning. Exchange of our debt, first, we had an operational issue, the first semester.
Even though we had a very good stockpile going on inside our warehouses before. Marcelo had actually told us last year we did not accomplish all the business inside the market with ECD. It's a strategy to actually leave a more flexible place inside a company, so we did not even have to go through this economic crisis. The bureaucracy involved for the company was not a very good thing. Now, the first trimester, we actually make for something around BRL 74 million in the ECD market. Along for the next year, we actually make for the fourth semester. We hope to reach the highs of capitation for BRL 100 million. So we expect these numbers to be slightly positive until the end of the year, showing that we have exchanged and optimized processes inside the BNDES for long-term negotiations.
We actually showed that we were able to make the exchange in a very successful way. That's translated in this graphic over here. The percentage of PNAP that actually improved 66% and made it now 78% instead of gross profit that we had, doing only a fourth of what we have inside our debts inside our company. 12% inside our average sellings along the year 2022, where we can actually have an average cost in a high of 10%. That it's a product of a strategy and a penny of our company, and we're pretty excited about it. A good thing about the profit generation actually is it meant boost administration inside our company along the semesters for the year, although we have a very tight logistics and rupture when it comes to the distribution of products. Our agent capital is making for the debt profile.
Being composed of a 79% along the year and 44% above five-year expense. When it comes to the initial income from BNDES we're going to evaluate even more. It's been aligned to the planned strategic of the company. So our development and research department can be graduated further, but requires the capital structure when it comes to a long-term proposition, so we can actually, by trying to negotiate this, put more than bent X managing and everything else. With all this, I'm making a conclusion about it. Get back to Juliana so we can begin a Q&A round. Thank you so much for the comparison.
Thank you, Bruno, as well, for your participation, for your enlightening. All right. The Q&A round is open.
You can utilize our space for Q&A, remembering that this transmission is going to be recorded and available on our site, ri.ourofino.com, and on our YouTube channel. We already have a question in our space here. I am going to switch over to Kleber so you can conduct this specific moment. Kleber, the words are yours.
Thank you, Ju. We have one question about practice. Good morning. Could you shed us a light about any changes that have been perceived in the first few weeks from Mitsui inside the business capital and made long-term inside our company for the business that we have? It has been a very recent operation yet, but we already have a relationship with Mitsui. It has been a negotiation with the shareholders inside the company that actually has been a very long relationship with them in terms of licensing.
As soon as this transaction was actually entered, it has been very well-received in Japan, and for Ouro Fino, a very media enterprise as well, with many other professional contacts getting in touch with us. We did not have time yet to explore many partnership opportunities. We have already been receiving proposals from Mitsui as well. We are not still discussing about the future prices inside the market, but we have a very good perspective on it. We have already some meetings scheduled with Japanese companies along with Mitsui to actually explore the potential of what we have. This is going to be something very dynamic. All the networking is actually going to be worked on.
I, myself, am actually going to Japan for the beginning of the year so we can actually understand Mitsui, so we can have the opportunity to leave our director board, so we can have the opportunity to have someone working on the place and working on the bureaucracy inside the company there to actually work and look for new opportunities as we have inside the windows of a gift that we have. It is a very important moment for us. For short, mid, and long term, we will bring out the answers that we have. I am not really sure about the technology, about the licensing, about the bureaucracy involved inside the whole process, but it would be a very positive thing. I hope that we can explore with a good partner, with Mitsui, the exponential, the quality of our product inside Asia as well. Any more questions?
I do not have any questions here showing up in the chat. If there are any questions available, I am going to get back over to Juliana so she can conduct the Q&A round.
Give it a couple of minutes, everyone can actually refresh. If there are any more questions to be made. I really wanted to make a few notifications, the investor team is actually available to everyone for any enlightening if you guys meet up on the transmissions and actually for the few days as well. We have a question from Bernardo, Kleber. Are you actually going to answer it?
Thank you for your question. I am actually going to translate it to everyone about a competitive scenario that we have. The competitive scenario is actually something pretty frightful, actually.
We then have global players inside of the market, and they have actually been disputing over a market that has been coveted by the whole world. The protein production sort of market as lives, actually searching for, keeping for the better results. In general terms, what we have available here in the market for the last three months for a bit more consolidation movements that we have in a sector of distribution and logistics for production animals in general, and a few transactions over it, they are based in investment requiring participations in the market, important participations for the Brazilian sector. It is a very polarized market. It has been directly to the production in agribusiness as well. Very strong groups are actually involved in it. But inside the very polarized context, it has been developed like this. So we had a few moments as well.
What we understand is, these movements that will help improve the growth inside the supply chain as a whole. There has been another question here from Gustavo. According to field research, are you guys looking for the projection of the increased rate of your production? When it comes to the specific market, it is a very good market. It has been growing a lot. Along the years of 2020, 2021, we had expected a kind of a euphoria inside this market. They have concentrated their income, but a distribution with, when it comes to the restaurant sector, to the beauties. So it has been pretty channeled to animal. The reduction tax was actually being reduced a lot. Looking, taking a step further on for the next year, we expect the market to actually get back to normality. It is a very positive thing to actually been told by.
We expect it to be something like 15%, 16% inside the market. We expect this kind of growth to actually happen naturally. So it is a very good market when it comes to the income, always been positioned when it comes to the solution terms and in terms of teamwork. The recent releases that we have regarding supplements has been pretty good. We also have our platform, our technology platform that has been already presented to the customers as well on the side of market. And we are always trying to reinforce our team. We do not have a great movement in terms of staff increase, something that has always been inside our planning, our strategic plan inside the company, but thank you a lot for the question. For the next one now. I believe there is another question in here. Ítalo, friend, good morning.
Could you please give a further explanation about biological products? Yes. We could mention that we have a very hard work and a finalization of specific stages and the development of few vaccines. We managed to actually create pilots from our plans from organizing that we need to do inside the enterprise, three batches that need to be concluded by the implemented organs. So we can write, so we can actually build the dossiers for health ministry. So that is almost the final stage of what the conclusions of what we have here.
Regarding the supplement stability, and we actually advanced a lot in that field. So we have been walking with this kind of engagement, the release of Zika virus vaccine from Ixorya plasam. And now we have advanced a lot in this year with the pilot of other important vaccines. Your question was a very important thing to actually mention.
Okay, we do not have any more questions. For a while, Kleber, we do not have any. So much for the gentleness of everyone who actually made questions. Remembering, pointing out that this transmission is going to be available on ri.ourofino.com and in our YouTube channel, youtube.com/ourofinosaudeanimal. Kleber mentioned our campaign when it comes to the movement, the agri is an awesome inside YouTube. You find materials over this moment, our TV programs, Ourofino em Campo, and in our programs, Amigo Pet, that is actually being turned on for pets companies releases. I am going to send the word over to Kleber to make his final considerations, and thank you for the opportunity to actually being around with you today.
Just wanted to point out two very important things that inside this month, we made last October, we had to release a corporative platform for development issues.
It is a base training for this more modern modality, something like of our internal Netflix, where all the training is actually being listed on videos. Beyond that, we are actually releasing, it is a very recent thing, our first secret for veterinarian industry inside the field. So we have a channel of actually being integrated with 16, 35, 18, 2,000, that would be the correct number, for producers. Mainly, the lesser products who are actually facing when it comes to accessory and support types, they can actually get in within work hours in touch with a specialized veterinarian to actually get orientations. So that is a very comforting thing to start our market, and I believe they are going to have the right kind of support. At the end, so that we can actually, we are actually motivated to look forward for the fourth semester.
We have faced elections, we have faced World Cup, but we have been working under any kind of context. We have been available for you guys, also bringing very good results. We have been very strong for the second semester to close the year in a very successful way. Thank you everyone for the trust, for the time that you have spent here with us. See you soon.